论文部分内容阅读
提要目的探讨Claudin-3在前列腺癌组织中的表达及其意义。方法用免疫组化法半定量测定前列腺癌80例、前列腺增生组织20例中Claudin-3的表达;用蛋白印迹结合图像分析法定量测定前列腺癌和前列腺增生组织的Claudin-3的表达。结果免疫组化及蛋白印迹均示前列腺癌组织中Claudin-3的表达显著高于良性前列腺增生组(P<0.01)。结论Claudin-3蛋白在前列腺癌组织中表达较前列腺增生组织中的表达明显上调,Claudin-3可能成为诊断前列腺癌的候选癌标。
Abstract Objective To investigate the expression of Claudin-3 in prostate cancer and its significance. Methods The expression of Claudin-3 in 80 cases of prostate cancer and 20 cases of benign prostatic hyperplasia were semi-quantitatively detected by immunohistochemistry. The expression of Claudin-3 in prostate cancer and benign prostatic hyperplasia was quantitatively determined by Western blotting and image analysis. Results Immunohistochemistry and Western blotting showed that the expression of Claudin-3 in prostate cancer tissues was significantly higher than that in benign prostatic hyperplasia (P <0.01). Conclusions The expression of Claudin-3 protein in prostate cancer tissues is significantly up-regulated compared with that in benign prostatic hyperplasia tissues. Claudin-3 may be a potential cancer marker in the diagnosis of prostate cancer.